Trial Profile

A RANDOMIZED CLINICAL TRIAL OF ORAL CLARITHROMYCIN IN COMMUNITY-ACQUIRED PNEUMONIA TO ATTENUATE INFLAMMATORY RESPONSES AND IMPROVE OUTCOMES (THE ACCESS TRIAL)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 23 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Apr 2024 Primary endpoint has been met (Change of baseline total sequential organ failure assessment (SOFA) score and/or change of baseline serum PCT; more than or equal to 30% decrease of SOFA score and/or favorable PCT kinetics (80% decrease from baseline or PCT <0.25 ng/ml)) , according to Results presented at the 34th Congress of the European Society of Clinical Microbiology and Infectious
10 Dec 2023 Status changed from active, no longer recruiting to completed.
11 Jan 2023 Planned primary completion date changed from 24 Jan 2023 to 10 Apr 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com